Novartis Malaria Program: Scale Masks Structural Resistance Threat and HTA Ceiling

Novartis Recognized by Fortune for Global Malaria Program

Novartis has been recognized by Fortune, earning a spot on its 2026 Change The World list for its significant and sustained malaria program. For over three decades, Novartis has been at the forefront of fighting malaria, a disease responsible for over 600,000 deaths annually, primarily in young children. The company's efforts include the discovery, development, and distribution of innovative antimalarial treatments, delivering more than 1.1 billion treatment courses worldwide, largely on a not-for-profit basis. This commitment has led to averting over 500,000 deaths and USD 24 billion in productivity losses in Africa in 2022 alone, alongside continuous R&D to combat emerging drug-resistant strains.

• Novartis has demonstrated a sustained, three-decade commitment to combating malaria, a leading cause of death globally. This dedication led to the introduction of the world's first artemisinin-based combination therapy (ACT) in 1999, which became the global standard of care for acute, uncomplicated malaria, effectively addressing the challenge of emerging drug resistance at the time.
• The company has achieved a remarkable scale in treatment delivery, distributing over 1.1 billion antimalarial treatment courses worldwide, predominantly on a not-for-profit basis. This includes more than 500 million doses of a child-friendly formulation, significantly contributing to global health by averting an estimated 500,000 deaths and USD 24 billion in productivity losses in Africa in 2022.
• Novartis continues to innovate in the fight against malaria, particularly against drug-resistant parasite strains. Recent breakthroughs include the 2025 introduction of the world's first antimalarial treatment for newborns and young infants (2-5 kg), which received WHO prequalification in 2026. Furthermore, their most advanced candidate, KLU156 (GanLum), has reported positive Phase III clinical trial results and has been submitted for regulatory approval.

Understanding the Enduring Global Burden of Malaria

In 2021, the global age-standardized incidence rate of malaria stood at 3,485.3 per 100,000 (95% uncertainty interval: 2,804.5–4,435.7), representing a 5.24% decrease since 1992. Despite this overall decline, the burden remains profoundly concentrated geographically: Sub-Saharan Africa recorded an age-standardized rate of 20,225.9 per 100,000 (95% UI: 16,033.5–25,862.6), accounting for 92% of all new malaria cases globally in 2021. Age-period-cohort analysis of data from 1992 to 2021 confirms that age-standardized malaria incidence rates generally declined across the highest-risk regions, though Sub-Saharan Africa experienced the smallest reduction, with a net drift of -0.74% (95% CI: -1.32 to 0.17) — the most modest improvement of any high-burden region examined.

Within the global distribution of disease, the 0–4 age group carries the highest risk, with incidence decreasing progressively with age. Data from Sao Tome and Principe — an island nation in West Africa — illustrate the trajectory possible with sustained intervention: the age-standardized incidence rate, age-standardized mortality rate, and age-standardized DALYs rate declined by 77.08%, 87.84%, and 82.21%, respectively, between 1990 and 2019, though a slight rebound in incidence was observed after 2015. Children under five in that setting nonetheless retained the highest disease burden relative to other age groups, consistent with global patterns.

A critical challenge compounding accurate incidence estimation is the systematic underreporting inherent to passive surveillance infrastructure. The World Health Organization estimates that routine surveillance detects only 14% of global malaria cases. Research in Madagascar's Ifanadiana District demonstrated that passive surveillance missed approximately 4 in every 5 malaria cases across all age groups, and 2 out of every 3 cases among children under five — underscoring that published incidence figures likely represent a substantial undercount of the true global burden.

Novartis's Pioneering Role in Malaria Treatment Evolution

Over the past five years, published trial data have reinforced the continued efficacy of artemisinin-based combination therapies (ACTs) as the cornerstone of uncomplicated Plasmodium falciparum malaria treatment, while simultaneously exposing critical geographic vulnerabilities. Studies conducted in Chad confirmed PCR-corrected adequate clinical and parasitological response (ACPR) rates of 97.8% to 100% for artemether-lumefantrine (AL) and 100% for artesunate-amodiaquine (AS-AQ) across all sites, with an absence of known pfkelch13 mutations associated with artemisinin partial resistance (ART-R). Similarly, trials in Equatorial Guinea reported PCR-adjusted cure rates of 92.4% to 100% for AL and 98.6% to 100% for AS-AQ, with no Pfkelch13 mutations linked to artemisinin resistance detected among 476 interpretable samples. However, data from Burkina Faso presented a starkly different picture: PCR-corrected 28-day efficacy for AL reached only 74% in Nanoro and 76% in Gourcy, and 42-day efficacy for dihydroartemisinin-piperaquine (DP) was 84% in Gourcy and 89% in Nanoro — findings the investigators concluded may warrant a change of first-line ACT in those sites.

Compounding these efficacy concerns, surveillance data from Eritrea documented a rising prevalence of the Pfkelch13 R622I mutation — increasing from 8.6% of isolates in 2016 to 21.0% in 2019 — alongside a corresponding rise in day-3 positivity from 0.4% to 4.2% over the same period. Patients carrying the 622I variant faced odds of day-3 positivity 6.2 times higher (95% CI 2.5 to 15.5) than those without it, and the World Health Organization definition of partial artemisinin resistance was met in Eritrea. Dual pfhrp2/pfhrp3 deletions — which threaten the performance of HRP2-based rapid diagnostic tests — were detected in 16.9% of parasites carrying the Pfkelch13 R622I mutation in Eritrea and in 2.3% of isolates in Chad, adding a diagnostic dimension to the resistance challenge. Pharmacokinetic data further nuanced the treatment picture: pregnant women demonstrated 21% higher elimination clearance of dihydroartemisinin compared to non-pregnant women, resulting in proportionally lower drug exposure and a potentially elevated risk of treatment failure in this vulnerable population.

Against this backdrop of resistance emergence and pharmacokinetic complexity, the vaccine pipeline has advanced meaningfully. The R21/Matrix-M candidate demonstrated vaccine efficacy of 74% (95% CI 63–82) and 77% (67–84) at six months in two adjuvant-dose groups in Burkina Faso children, with efficacy remaining at 77% (67–84) at one year in the lower-adjuvant group. Following a booster dose administered 12 months after the primary series, efficacy reached 71% (95% CI 60–78) in the low-dose adjuvant group and 80% (72–85) in the high-dose adjuvant group, with 2,285 (95% CI 1,911–2,568) malaria cases averted per 1,000 child-years at risk in the second year. The blood-stage candidate RH5.1/Matrix-M, evaluated in a phase 2b trial in Burkina Faso, showed a vaccine efficacy of 55% (95% CI 20–75%; p=0.0071) under a delayed third-dose regimen, with high anti-RH5.1 IgG concentrations and in vitro growth inhibition activity of 79.0% (SD 14.3) against P. falciparum. Taken together, these data reflect a treatment landscape in active transition — one in which ACT stewardship, resistance surveillance, and vaccine deployment are increasingly interdependent strategic priorities.

Addressing Emerging Drug Resistance in Malaria Treatment

Antimalarial drug resistance spans multiple drug classes and is driven by a range of molecular mechanisms, from point mutations in target proteins to gene copy number variations. Surveillance of these markers is critical for guiding treatment policy and preserving the efficacy of artemisinin-based combination therapies (ACTs) and their partner drugs.

• K13 mutations and artemisinin resistance: Mutations in the P. falciparum K13 protein — including F446I, M476I, Y493H, R539T, N458Y, C469Y, F495L, and P413A — are the primary drivers of partial artemisinin resistance, defined clinically as delayed parasite clearance following artemisinin-based treatment. The P413A mutation, located in the BTB/POZ domain upstream of the Kelch propeller domain, demonstrates that the propeller domain is not the sole mediator of K13-associated resistance. Different mutations carry distinct fitness costs: N458Y confers a significant fitness penalty, while F446I — the predominant mutation in northern Myanmar — shows only marginal fitness loss, partially explaining its high regional prevalence.

• Proteasome inhibition as a strategy to reverse artemisinin resistance: A Plasmodium-selective proteasome inhibitor strongly synergized dihydroartemisinin activity in P. berghei K13 mutant lines, providing evidence that proteasome inhibition can offset K13 mutation-mediated artemisinin resistance in vivo.

• Pfdhfr and Pfdhps mutations and sulfadoxine-pyrimethamine (SP) resistance: Resistance to SP is conferred by mutations in P. falciparum dihydrofolate reductase (Pfdhfr) and dihydropteroate synthase (Pfdhps). The combined Pfdhfr/Pfdhps quintuple mutation is strongly associated with SP resistance. Following SP withdrawal in North Western Ethiopia, the frequency of the triple Pfdhfr mutation decreased significantly from 50.8% to 15.9% (P<0.001), and the quintuple mutation decreased from 40.7% to 13.6% (P<0.0001), consistent with reduced fitness of resistant parasites in the absence of drug pressure.

• Cytochrome b (cytb) mutations and atovaquone-proguanil (AP) resistance: AP resistance is mediated by point mutations in P. falciparum cytochrome b (pfcytb). Known resistance-associated mutations include Y268S and Y268C; a novel mutation, I258M, was identified in one of two AP treatment failures in travelers returning from Nigeria. In Cambodia, cytb mutation played a minor role in AP treatment failures, with only one of 14 recrudescent cases harboring the Y268C mutation, arising de novo rather than from pre-existing low-frequency variants.

• PfCRT mutations and piperaquine resistance: Newly emerged mutations in the P. falciparum chloroquine resistance transporter (PfCRT) — including T93S, H97Y, and F145I — can confer piperaquine resistance independently of amplified plasmepsin II (pfpm2). In northern Cambodia, these PfCRT mutations increased to >98% prevalence by 2017 following the adoption of dihydroartemisinin-piperaquine. Notably, none of these mutations were detected in 268 isolates from southeastern Nigeria, indicating piperaquine remains viable in that region.

• Copy number variation (CNV) in pfpm2 and pfmdr1: Increased copy number of pfpm2 confers parasite tolerance to piperaquine, while increased pfmdr1 copy number is associated with resistance to mefloquine and decreased susceptibility to lumefantrine — both ACT partner drugs. In southern Angola, 9.8% of isolates carried increased pfpm2 CNV and 8.9% carried increased pfmdr1 CNV, representing the first such evidence from that region.

• Cross-resistance and multi-target resistance acquisition: In vitro selection studies using diverse antimalarial compounds demonstrate that resistant parasites can emerge across targets including pfatp4, cytochrome bc1, pfcarl, pfdhod, pfcrt, pfmdr, pfdhfr, cytoplasmic prolyl t-RNA synthetase, and hsp90. Of 48 in vitro selections, 23 yielded resistant parasites, with time to resistance onset ranging from 15 to 300 days, suggesting that fast-killing compounds may result in slower onset of clinical resistance.

Sustaining the Fight: Pharma's Enduring Role in Malaria Eradication

The ongoing recognition of Novartis's malaria program highlights a critical intersection of pharmaceutical innovation, public health commitment, and the enduring fight against a formidable global disease. While significant progress has been made in reducing the malaria burden through interventions like vector control and artemisinin-based combination therapies (ACTs), the battle is far from over. The persistent threat of drug resistance, particularly from Plasmodium falciparum strains originating in Southeast Asia, underscores the necessity for continuous research and development into novel antimalarial agents.

Companies like Novartis, with their long-term, not-for-profit engagement, are not just providing treatments; they are actively shaping the future of malaria control. Their pipeline, including candidates like KAE609 and KAF156, aims to address the evolving parasite landscape by targeting transmission and liver-stage forms, which is crucial for achieving disease elimination. However, the path to eradication is fraught with challenges:

• Evolving Resistance: The emergence of even mild mutator phenotypes in parasites suggests a continuous arms race, demanding a robust and agile drug discovery pipeline.

• Implementation Gaps: Even with effective drugs, real-world challenges persist. Studies indicate that community health worker programs, while promising, face hurdles in uptake and fidelity, especially in urban settings, due to factors like lack of awareness or drug stock-outs.

• Pediatric Adherence: Administering antimalarials to young children remains difficult, emphasizing the need for user-friendly formulations that ensure accurate dosing and improve compliance.

This sustained effort by Novartis demonstrates that combating malaria requires a multi-pronged approach: innovative drug discovery, accessible distribution, and a deep understanding of the practical challenges in endemic regions. The pharmaceutical industry's role extends beyond drug development to fostering sustainable health systems and ensuring that life-saving treatments reach those who need them most, even when profitability is not the primary driver.